For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.It also includes access to the Zacks Style Scores. What are the Zacks Style Scores? The Zacks Style S ...

Novavax (NVAX) reported first-quarter 2025 earnings of $2.93 per share, which beat the Zacks Consensus Estimate of 71 cents. In the year-ago quarter, the company reported a loss of $1.05 per share.Quarterly revenues totaled $667 million compared with $94 million in the year-ago period. The reported figure beat the Zacks Consensus Estimate of $212 million. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar)More on NVAX’s EarningsNovavax recorded $622 million in product sales compared wit ...

On Thursday, Novavax Inc. NVAX reported first-quarter 2025 sales of $667 million, compared to $94 million a year ago, beating the consensus of $343.85 million.Higher product sales for the first quarter of 2025 were primarily due to $603 million of revenue recognized with the termination of two Advance Purchase Agreements (APA) and related to cash received in prior years. $45 million of Licensing, Royalties, & Other Revenue in the first quarter of 2025 was higher than the prior year due to $40 million of San ...

Novavax (NVAX) came out with quarterly earnings of $2.93 per share, beating the Zacks Consensus Estimate of $0.71 per share. This compares to loss of $1.05 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 312.68%. A quarter ago, it was expected that this vaccine maker would post a loss of $0.75 per share when it actually produced a loss of $0.51, delivering a surprise of 32%.Over the last four quarters, the company has surpasse ...

Novavax (NVAX) Q1 2025 Earnings Call May 08, 2025 08:30 AM ET Company Participants Luis Sanay - Vice President of Investor RelationJohn Jacobs - President & CEORuxandra Draghia-Akli - Executive Vice President, Head of Research & DevelopmentJim Kelly - Executive Vice President, Chief Financial Officer and TreasurerMayank Mamtani - Senior Managing DirectorJohn Trizzino - President & COO Conference Call Participants Roger Song - Senior Equity Research AnalystAlec Stranahan - AnalystThomas Shrader - Equity Rese ...

Novavax (NVAX) Q1 2025 Earnings Call May 08, 2025 08:30 AM ET Speaker0 Good morning, and welcome to Novavax First Quarter twenty twenty five Financial Results and Operational Highlights Conference Call. All participants will be in a listen only mode. After today's presentation, there will be an opportunity to ask questions. Please note, this event is being recorded. I'd now like to turn the conference over to Luis Sannai, Vice President, Investor Relations. Please go ahead. Speaker1 Good morning, and thank ...

First Quarter 2025 Financial Results and Operational Highlights May 8, 2025 © 2025 NOVAVAX. All rights reserved. Cautionary Note Regarding Forward-Looking Statements This presentation includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as "anticipate," "expect," "plan," "could," "may," "will," "believe," "estimate," "forecast," "goal," "project," and other words of similar meaning. These forward-looking statements address various matters ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (State or other jurisdiction of incorporation or organization) Delaware 22-2816046 (I.R.S. Employer Identification No.) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 000-26 ...

We expect Novavax (NVAX) to surpass expectations when it reports first-quarter 2025 earnings on May 8, before the opening bell. The company’s earnings beat estimates by 32% in the last reported quarter.The Zacks Consensus Estimate for sales is pegged at $71.84 million, while that for earnings is pinned at 19 cents per share. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar)Factors Shaping NVAX’s Upcoming ResultsStarting this year, pharma giant Sanofi (SNY) acquired exclusive rights to ...

Company Performance - Novavax (NVAX) closed at $6.41, unchanged from the previous session, lagging behind the S&P 500's 1.47% gain [1] - Over the past month, Novavax shares have increased by 14.46%, while the Medical sector has decreased by 2.95% and the S&P 500 by 0.47% [1] Earnings Forecast - Novavax is expected to report an EPS of $0.19 on May 8, 2025, representing a 118.1% increase year-over-year [2] - Revenue is forecasted to be $71.84 million, indicating a 23.47% decline compared to the same quarter of the previous year [2] - For the entire year, earnings are projected at $0.63 per share and revenue at $536.24 million, reflecting changes of +151.22% and -21.39% respectively compared to the previous year [3] Analyst Estimates - Recent adjustments to analyst estimates for Novavax indicate changing business trends, with upward revisions suggesting positive sentiment towards the company's operations [4] - The Zacks Rank system, which incorporates these estimate changes, currently ranks Novavax at 3 (Hold) [6] Valuation Metrics - Novavax has a Forward P/E ratio of 10.2, which is lower than the industry average of 17.32, indicating it is trading at a discount [7] - The company has a PEG ratio of 0.24, significantly below the industry average of 1.34, suggesting favorable valuation relative to expected earnings growth [8] Industry Context - The Medical - Biomedical and Genetics industry, which includes Novavax, holds a Zacks Industry Rank of 84, placing it in the top 35% of over 250 industries [9] - Research indicates that industries in the top 50% outperform those in the bottom half by a factor of 2 to 1 [9]